Cytokine-based transformation of immune surveillance into tumor-promoting inflammation

Oncogene

Volumn 27, Issue 45, 2008, Pages 5913-5919

  Mumm, J B ^a   Oft, M ^a  

^a Schering Plough Biopharma ^*  (United States)

Author keywords

IL 12; IL 23; Inflammation; Th17; Tumor immune surveillance

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN RECOGNITION; CANCER GROWTH; HELPER CELL; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; CELL PROLIFERATION; CYTOKINES; HUMANS; IMMUNOLOGIC SURVEILLANCE; INFLAMMATION; INTERLEUKIN-12; INTERLEUKIN-23; INTERLEUKIN-6; MODELS, BIOLOGICAL; NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

MAMMALIA;

EID: 53549100997     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.275     Document Type: Review

References (78)

1. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB et al. (2006). Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091: 151-169.
2. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G et al. (1998). Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187: 461-468.
3. Ancrile B, Lim KH, Counter CM. (2007). Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 1714-1719.
4. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS et al. (1997). Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3: 409-417.
5. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S et al. (2000). Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6: 583-588.
6. Baffet G, Braciak TA, Fletcher RG, Gauldie J, Fey GH, Northemann W. (1991). Autocrine activity of interleukin 6 secreted by hepatocarcinoma cell lines. Mol Biol Med 8: 141-156.
7. Balkwill F, Charles KA, Mantovani A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
8. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A et al. (2004). TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501.
9. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
10. Betz UA, Muller W. (1998). Regulated expression of gp130 and IL-6 receptor alpha chain in T cell maturation and activation. Int Immunol 10: 1175-1184.
11. Bierie B, Moses HL. (2006). Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520.
12. Blankenstein T. (2005). The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17: 180-186.
13. Borkowski TA, Letterio JJ, Farr AG, Udey MC. (1996). A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J Exp Med 184: 2417-2422.
14. Bowman EP, Chackerian AA, Cua DJ. (2006). Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis 19: 245-252.
15. Brandes ME, Mai UE, Ohura K, Wahl SM. (1991). Type I transforming growth factor-beta receptors on neutrophils mediate chemotaxis to transforming growth factor-beta. J Immunol 147: 1600-1606.
16. Cebon J, Jager E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W et al. (2003). Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 3: 7.
17. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S et al. (2006). IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203: 2577-2587.
18. Chen W, Jin W, Tian H, Sicurello P, Frank M, Orenstein JM et al. (2001). Requirement for transforming growth factor beta1 in controlling T cell apoptosis. J Exp Med 194: 439-453.
19. Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature 420: 860-867.
20. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B et al. (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
21. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
22. Derynck R, Akhurst RJ, Balmain A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129.
23. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
24. Feldmann M, Maini RN. (2001). Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19: 163-196.
25. Folkman J. (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
26. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
27. Happel KI, Zheng M, Young E, Quinton LJ, Lockhart E, Ramsay AJ et al. (2003). Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 170: 4432-4436.
28. Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF et al. (2007). Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 25: 4542-4549.
29. Jager E, Jager D, Knuth A. (2003). Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 106: 817-820.
30. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ et al. (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561.
31. Kastelein RA, Hunter CA, Cua DJ. (2007). Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 25: 221-242.
32. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R et al. (1986). Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163: 1037-1050.
33. Knuth A, Danowski B, Oettgen HF, Old LJ. (1984). T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci USA 81: 3511-3515.
34. Kolls JK, Linden A. (2004). Interleukin-17 family members and inflammation. Immunity 21: 467-476.
35. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J et al. (2007). Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-6733.
36. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J et al. (2003). Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63: 3560-3566.
37. Langowski JL, Kastelein RA, Oft M. (2007). Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 28: 207-212.
38. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K et al. (2006). IL-23 promotes tumour incidence and growth. Nature 442: 461-465.
39. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.
40. Letterio JJ. (2005). TGF-beta signaling in T cells: roles in lymphoid and epithelial neoplasia. Oncogene 24: 5701-5712.
41. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. (2006). Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99-146.
42. Lin WW, Karin M. (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183.
43. Liu SJ, Tsai JP, Shen CR, Sher YP, Hsieh CL, Yeh YC et al. (2007). Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J Leukoc Biol 82: 354-360.
44. Lo CH, Lee SC, Wu PY, Pan WY, Su J, Cheng CW et al. (2003). Antitumor and antimetastatic activity of IL-23. J Immunol 171: 600-607.
45. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. (2005). IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121: 977-990.
46. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO et al. (2006). Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231-234.
47. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T et al. (2007). TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8: 1390-1397.
48. Mocellin S, Rossi CR, Pilati P, Nitti D. (2005). Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16: 35-53.
49. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N et al. (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5: 828-831.
50. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-3494.
51. Nakae S, Nambu A, Sudo K, Iwakura Y. (2003). Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171: 6173-6177.
52. Novelli F, Casanova JL. (2004). The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev 15: 367-377.
53. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T et al. (2003). Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627.
54. Oft M, Akhurst RJ, Balmain A. (2002). Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 4: 487-494.
55. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J et al. (2002). A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168: 5699-5708.
56. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J. (2006). Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep 15: 179-185.
57. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM et al. (1986). Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83: 4167-4171.
58. Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD. (2008). Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 58: 82-87.
59. Rose-John S, Scheller J, Elson G, Jones SA. (2006). Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80: 227-236.
60. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL et al. (2005). Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175: 6169-6176.
61. Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ et al. (2003). An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2: 445-451.
62. Sepulveda H, Cerwenka A, Morgan T, Dutton RW. (1999). CD28, IL-2-independent costimulatory pathways for CD8T lymphocyte activation. J Immunol 163: 1133-1142.
63. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. (2001). Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12: 33-40.
64. Strobl H, Riedl E, Scheinecker C, Bello-Fernandez C, Pickl WF, Rappersberger K et al. (1996). TGF-beta 1 promotes in vitro development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol 157: 1499-1507.
65. Szlosarek P, Charles KA, Balkwill FR. (2006). Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42: 745-750.
66. Szlosarek PW, Balkwill FR. (2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4: 565-573.
67. Trinchieri G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
68. Trinchieri G, Pflanz S, Kastelein RA. (2003). The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19: 641-644.
69. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R et al. (2006). Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25: 309-318.
70. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B et al. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
71. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES et al. (2002). Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188: 51-64.
72. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB et al. (1987). Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 84: 5788-5792.
73. Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN. (2000). Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol 165: 7240-7245.
74. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD et al. (2007). Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8: 950-957.
75. Wong GH, Bartlett PF, Clark-Lewis I, Battye F, Schrader JW. (1984). Inducible expression of H-2 and Ia antigens on brain cells. Nature 310: 688-691.
76. Wrzesinski SH, Wan YY, Flavell RA. (2007). Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 13: 5262-5270.
77. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al. (2008). Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13: 23-35.
78. Zhang X, Giangreco L, Broome HE, Dargan CM, Swain SL. (1995). Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J Exp Med 182: 699-709.